KR20170096008A - 2형 당뇨병의 치료를 위한 가교결합된 폴리디알리민 공중합체 - Google Patents

2형 당뇨병의 치료를 위한 가교결합된 폴리디알리민 공중합체 Download PDF

Info

Publication number
KR20170096008A
KR20170096008A KR1020177019820A KR20177019820A KR20170096008A KR 20170096008 A KR20170096008 A KR 20170096008A KR 1020177019820 A KR1020177019820 A KR 1020177019820A KR 20177019820 A KR20177019820 A KR 20177019820A KR 20170096008 A KR20170096008 A KR 20170096008A
Authority
KR
South Korea
Prior art keywords
copolymer
formula
subject
copolymer according
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177019820A
Other languages
English (en)
Korean (ko)
Inventor
프라딥 케이. 달
로버트 제이. 밀러
스티븐 씨. 폴로모스카닉
필리프 유스트 라르젠
토마스 휘브슐레
토르스텐 슈밋츠
이안 데이비슨
피터 맥도넬
친예레 아그부그바
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Publication of KR20170096008A publication Critical patent/KR20170096008A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/08—Epoxidation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0025—Crosslinking or vulcanising agents; including accelerators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/15—Heterocyclic compounds having oxygen in the ring
    • C08K5/151—Heterocyclic compounds having oxygen in the ring having one oxygen atom in the ring
    • C08K5/1515—Three-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F26/04—Diallylamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Epoxy Resins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177019820A 2014-12-18 2015-12-16 2형 당뇨병의 치료를 위한 가교결합된 폴리디알리민 공중합체 Withdrawn KR20170096008A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093751P 2014-12-18 2014-12-18
US62/093,751 2014-12-18
PCT/US2015/066006 WO2016100456A2 (en) 2014-12-18 2015-12-16 Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
KR20170096008A true KR20170096008A (ko) 2017-08-23

Family

ID=55221501

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177019820A Withdrawn KR20170096008A (ko) 2014-12-18 2015-12-16 2형 당뇨병의 치료를 위한 가교결합된 폴리디알리민 공중합체

Country Status (27)

Country Link
US (1) US11267924B2 (enExample)
EP (1) EP3233090A2 (enExample)
JP (2) JP6866293B2 (enExample)
KR (1) KR20170096008A (enExample)
CN (1) CN107250189A (enExample)
AR (1) AR103175A1 (enExample)
AU (1) AU2015362590A1 (enExample)
BR (1) BR112017012794A2 (enExample)
CA (1) CA2971204A1 (enExample)
CL (1) CL2017001579A1 (enExample)
CO (1) CO2017007119A2 (enExample)
CR (1) CR20170323A (enExample)
DO (1) DOP2017000140A (enExample)
EA (1) EA201791380A1 (enExample)
EC (1) ECSP17045972A (enExample)
GT (1) GT201700133A (enExample)
HK (1) HK1251449A1 (enExample)
IL (1) IL252899A0 (enExample)
MA (2) MA41202A (enExample)
MX (1) MX2017007966A (enExample)
PE (1) PE20171510A1 (enExample)
PH (1) PH12017501120A1 (enExample)
SG (1) SG11201704840RA (enExample)
TN (1) TN2017000253A1 (enExample)
TW (1) TW201636030A (enExample)
UY (1) UY36457A (enExample)
WO (1) WO2016100456A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
US10479865B2 (en) * 2017-11-01 2019-11-19 Strides Shasun Limited Process for the preparation of sevelamer carbonate
JP7753187B2 (ja) * 2019-08-07 2025-10-14 ソルベンタム インテレクチュアル プロパティズ カンパニー 架橋グアニジニル含有ポリマーを含有する物品及びその使用
EP4031553A4 (en) * 2019-09-20 2023-11-01 Glyscend, Inc. POLYMERS WITH SUBSTITUTED PHENYLBORONIC ACID AND METHOD OF USE
AU2021431510A1 (en) * 2021-03-01 2023-09-28 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
MX2024005969A (es) 2022-05-30 2024-06-11 Zealand Pharma As Formulaciones liquidas de analogos de amilina.

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2456428A (en) 1944-10-11 1948-12-14 Shell Dev Polyallyl amine and related polymeric amines
BE580490A (fr) 1958-07-15 1960-01-08 Merck & Co Inc Compositions et procédés pour abaisser la teneur en cholestérol du sang
US3104205A (en) 1959-12-17 1963-09-17 Warner Lambert Pharmaceutical Deodorant composition comprising the copper complex of the copolymer of allylamine and methacrylic acid
US3308020A (en) 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3332841A (en) 1961-10-04 1967-07-25 Lilly Co Eli Method of treating hyperacidity
BE640616A (enExample) 1962-12-19
US3293195A (en) 1963-11-29 1966-12-20 Ritter Pfaudler Corp Ion exchange resins prepared from a mixed resin of vinyl pyridine copolymers and epihalohydrins-polyalkylene polyamines and methods of making and using same
US3624209A (en) 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
DE1927336A1 (de) 1968-06-17 1969-12-18 Upjohn Co Orale Dosierungsform zur Bekaempfung von Hypercholesterinaemie
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US3980770A (en) 1971-06-04 1976-09-14 Pharmacia Aktiebolag Polymerization products containing amino groups useful in serum cholesterol level control
CH604722A5 (enExample) 1973-02-09 1978-09-15 Sandoz Ag
AR206115A1 (es) 1973-06-11 1976-06-30 Merck & Co Inc Procedimiento para preparar un polimero lineal no ramificado y no reticulado
US4205064A (en) 1973-06-11 1980-05-27 Merck & Co., Inc. Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides]
US4016209A (en) 1975-04-23 1977-04-05 Merck & Co., Inc. 3-[N'-(3-Halopropyl)-N-'-methylamino]-N,N,N-trimethyl-1-propanaminium halide and acid addition salts thereof
US4181718A (en) 1975-12-29 1980-01-01 Mason Norbert S Polyanion-stabilized aluminum hydrogels
US4071478A (en) 1976-06-07 1978-01-31 Merck & Co., Inc. Controlled partially cross-linked 3,3-ionenes
US4183918A (en) 1977-03-08 1980-01-15 Exxon Research & Engineering Co. Detoxifying-medicinal emulsions
GB1573487A (en) 1977-05-23 1980-08-28 Bristol Myers Co Bile acid binding composition
US4143130A (en) 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4368725A (en) 1977-11-11 1983-01-18 Mcclintock Michael Solar energy collector
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4247393A (en) 1979-01-11 1981-01-27 Wallace Richard A Hemodialysis assist device
US4439419A (en) 1980-02-20 1984-03-27 The Upjohn Company Method of treating gastric hyperacidity in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance as epichlorhydrin
US4344993A (en) 1980-09-02 1982-08-17 The Dow Chemical Company Perfluorocarbon-polymeric coatings having low critical surface tensions
IE52006B1 (en) 1980-12-12 1987-05-13 Smith & Nephew Ass Polymers of diallyl ammonium monomers pharmaceutical compositions thereof
US4504640A (en) 1982-05-19 1985-03-12 Nitto Boseki Co., Ltd. Process for producing monoallylamine polymer
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
DE3572985D1 (en) 1984-05-11 1989-10-19 Bristol Myers Co Novel bile sequestrant resin and uses
US4631305A (en) 1985-03-22 1986-12-23 The Upjohn Company Polymeric material as a disintegrant in a compressed tablet
DE3541511A1 (de) 1985-11-19 1987-05-21 Grace W R Ab Promoter fuer die papierleimung, verfahren zu dessen herstellung und dessen verwendung
AU628389B2 (en) 1988-08-26 1992-09-17 Pharmacia & Upjohn Company Fine-beaded colestipol hydrochloride
GB8829835D0 (en) 1988-12-21 1989-02-15 Smith Kline French Lab Compounds
DE3901527A1 (de) 1989-01-20 1990-07-26 Hoechst Ag Alkylierte polyethyleniminderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel sowie pharmazeutische praeparate
US6274713B1 (en) 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
US5136032A (en) 1989-12-07 1992-08-04 Daicel Chemical Industries, Ltd. Method for separating phosphopolyol compounds using a separating agent
US5053423A (en) 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
JPH0687974B2 (ja) 1990-03-27 1994-11-09 忠一 平山 発熱物質の吸着材料
DE4010271A1 (de) 1990-03-30 1991-10-02 Basf Ag Verfahren zur herstellung von ethylenpolymerisaten bei druecken oberhalb von 500 bar in einem rohrreaktor mit einspritzfinger
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
RU1808015C (ru) 1990-12-27 1993-04-07 Владимир Андреевич Шевченко Способ защиты млекопитающих от воздействи гамма-излучени
US5055197A (en) 1991-04-05 1991-10-08 Rohm And Haas Company Process for removing residual monomers and oligemers from amine-containing polymers
US5108767A (en) 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
ES2124736T3 (es) 1991-07-03 1999-02-16 Upjohn Co Comprimidos con alto contenido de clorhidrato de colestipol.
EP0534304A1 (de) 1991-09-21 1993-03-31 Hoechst Aktiengesellschaft Cycloalkylierte Polyethyleniminderivate und ihre Verwendung als Hypolipidämika
SE470006B (sv) 1991-09-26 1993-10-25 Corline Systems Ab Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
DK0580079T3 (da) 1992-07-22 1997-06-30 Hoechst Ag Tværbundne, nitrogenholdige vinylcopolymerer, fremgangsmåde til deres fremstilling samt anvendelse af disse forbindelser
ATE159262T1 (de) 1992-07-22 1997-11-15 Hoechst Ag Hydrophile zentren aufweisende polyvinylamin- derivate, verfahren zu ihrer herstellung sowie die verwendung der verbindungen als arzneimittel, wirkstoffträger und nahrungsmittelhilfsstoff
RU95107405A (ru) 1992-08-20 1997-02-10 Е. И. Дюпон Де Немур энд Компани (US) Сшитая полимерная аммониевая соль, фармацевтическая композиция, способ снижения содержания холестерина в плазме крови, способ усиления экскреции желчных кислот
US5302531A (en) 1992-10-22 1994-04-12 Miles Inc. Composition for the semiquantitative determination of specific gravity of a test sample
DE69330595T2 (de) 1992-11-25 2002-05-23 Ajinomoto Co., Inc. Zubereitungen und Nahrungsmittel enthaltend Mineralien und Poly-gamma-Glutaminsäure
DE69410995T2 (de) 1993-02-17 1998-11-05 British Technology Group Ltd., London 1 guanidino gruppen enthaltende polymere zur verwendung in der therapie
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
WO1994027620A1 (en) 1993-06-02 1994-12-08 Geltex Pharmaceuticals, Inc. Compositions and process for removing bile salts
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
JPH0788181A (ja) * 1993-09-21 1995-04-04 Mitsubishi Rayon Co Ltd エンドトキシン吸着材及び製法
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
WO1996021454A1 (en) 1995-01-12 1996-07-18 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
GB9503061D0 (en) 1995-02-16 1995-04-05 British Tech Group Polymeric compounds
JP2936129B2 (ja) 1995-04-12 1999-08-23 セイコー精機株式会社 防食構造
FI104823B (fi) 1996-06-24 2000-04-14 Borealis Polymers Oy Likaantumista estävä päällyste
JP3389493B2 (ja) 1997-04-04 2003-03-24 中外製薬株式会社 リン酸結合性ポリマー製剤
TW592727B (en) 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
DE19835467A1 (de) 1998-08-06 2000-02-17 Elenac Gmbh Feststoffreaktor mit antistatischer Beschichtung zur Durchführung von Reaktionen in der Gasphase
TW568788B (en) 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
US6500527B2 (en) 2001-02-01 2002-12-31 3M Innovative Properties Company Image receptor sheet
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
ITMI20021718A1 (it) 2002-07-31 2004-02-01 Sematic Italia Spa Interruttore di sicurezza con sistema elettronico programmabile.
AU2004311849B2 (en) 2003-12-31 2009-04-02 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
US20060024368A1 (en) 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
EP1810689A4 (en) * 2004-10-15 2009-07-22 Mitsubishi Tanabe Pharma Corp MEANS FOR THE PREVENTION AND / OR TREATMENT OF DIABETES
US20060177415A1 (en) 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
EP2016947A1 (en) * 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Novel one step process for preparing cross-linked poly(allylamine) polymers
PA8807201A1 (es) * 2007-12-14 2009-07-23 Genzyme Corp Composiciones farmaceuticas
CN106478948B (zh) 2010-02-24 2019-05-07 瑞立普萨公司 用作胆汁酸螯合剂的聚咪唑
JP6258586B2 (ja) 2010-02-24 2018-01-10 レリプサ， インコーポレイテッド 胆汁酸捕捉剤として使用するためのアミンポリマー
CN105017481B (zh) 2010-02-24 2018-10-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
US20130156720A1 (en) * 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
PE20151766A1 (es) * 2013-03-15 2015-12-11 Genzyme Corp Agentes quelantes de precursores de producto final de glicacion avanzada (age)

Also Published As

Publication number Publication date
EP3233090A2 (en) 2017-10-25
MX2017007966A (es) 2018-03-15
WO2016100456A3 (en) 2016-08-18
PH12017501120A1 (en) 2018-01-08
CA2971204A1 (en) 2016-06-23
DOP2017000140A (es) 2017-07-31
ECSP17045972A (es) 2017-11-30
TW201636030A (zh) 2016-10-16
BR112017012794A2 (pt) 2018-01-02
CN107250189A (zh) 2017-10-13
SG11201704840RA (en) 2017-07-28
IL252899A0 (en) 2017-08-31
UY36457A (es) 2016-07-29
CL2017001579A1 (es) 2018-03-23
PE20171510A1 (es) 2017-10-20
AR103175A1 (es) 2017-04-19
GT201700133A (es) 2019-09-17
WO2016100456A2 (en) 2016-06-23
US20160177019A1 (en) 2016-06-23
TN2017000253A1 (en) 2018-10-19
JP6866293B2 (ja) 2021-05-12
HK1251449A1 (zh) 2019-02-01
MA41202A (fr) 2017-10-24
MA40697A1 (fr) 2018-01-31
CO2017007119A2 (es) 2017-08-18
CR20170323A (es) 2017-08-22
AU2015362590A1 (en) 2017-08-03
JP2018501358A (ja) 2018-01-18
US11267924B2 (en) 2022-03-08
EA201791380A1 (ru) 2018-03-30
JP2021063229A (ja) 2021-04-22

Similar Documents

Publication Publication Date Title
JP2021063229A (ja) ２型糖尿病の処置のための架橋ポリジアリルアミンコポリマー
EP4537816A2 (en) Treatment of type-2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof
US9284283B2 (en) Macrocyclic compounds for modulating IL-17
CN102387704A (zh) S1p5受体的激动剂和拮抗剂，和其用法
CZ20024105A3 (cs) Glukagonoví antagonisté/inverzní agonisté
JP6498705B2 (ja) 代謝障害の治療に用いるためのジヒドロピリジノンｍｇａｔ２阻害剤
EA022395B1 (ru) Соединение пиперидинила в качестве модулятора активности хемокинового рецептора
JP2023550543A (ja) 二環式化合物及び疾患の治療のためのその使用
US20200237688A1 (en) Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
US11999676B2 (en) Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
CN101821227A (zh) 激素敏感性脂酶调节剂及使用方法
US8436025B2 (en) Compounds and methods for PKC theta inhibition
JP2008542311A5 (enExample)
US11318111B2 (en) CCL5 inhibitors
JP5486008B2 (ja) １‐ブチル‐２‐ヒドロキシアラルキルピペラジン誘導体およびその抗鬱剤としての使用
WO2014197961A1 (en) Non-agglomerating bioconjugates of amylin-mimetic compounds and polyethyleneglycol
EP4518866A1 (en) Methods of treating fibrosis
EP4305026B1 (en) Anti-inflammatory carboxamide derivatives
WO2024059200A1 (en) Nek7 inhibitors
JP2006506394A (ja) 線維症、アルツハイマー病および他の疾病の治療のためのｃｃｒ１拮抗剤としてのピペラジンスルフォン酸誘導体の使用
TWI892182B (zh) 吡唑化合物、製備方法、其醫藥組合物及其用途
KR20240018292A (ko) 항염증 조성물
WO2024108090A1 (en) Methods of treating inflammatory conditions
HK40121453A (zh) 用於治疗纤维化的磷酸甘油酸脱氢酶抑制剂
CA3195137A1 (en) Substituted aromatic compounds and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202